NasdaqCM:PVLABiotechs
Assessing Palvella Therapeutics After Its 666.8% Surge and Late Stage Pipeline Progress
Wondering if Palvella Therapeutics is still a smart buy after its massive run up, or if the market has already priced in the story, you are not alone. That is exactly what this breakdown will tackle.
After an eye catching 666.8% return year to date, the stock has cooled slightly in the last week with a 4.9% pullback but is still up 10.9% over the past month.
Recent headlines have focused on Palvella's progress in late stage development for treatments targeting rare dermatologic diseases...